Profusa Stock Price, News & Analysis

Profusa, Inc. (Nasdaq: PFSA) is a commercial stage digital health and medical technology company in the healthcare sector focused on biosensing solutions. Based in Berkeley, California, Profusa is developing a next-generation technology platform that enables the continuous monitoring of an individual’s biochemistry using tissue-integrated sensors and an intelligent data platform. The company’s approach is aimed at generating actionable, medical-grade data that can be used for both personal and clinical decision-making.

According to Profusa’s public disclosures, its platform centers on long-lasting, injectable and affordable biosensors designed to become integrated with tissue and transmit data continuously. This data is intended to provide what the company describes as a personalized biochemical signature that clinicians can trust and rely on. Profusa characterizes itself as being led by scientific founders, an experienced management team and a board of directors focused on advancing this new generation of tissue-integrated sensors.

Core technology and Lumee Oxygen tissue monitoring

Profusa’s primary commercial focus is its Lumee Oxygen tissue monitoring technology. Company materials describe Lumee as an oxygen tissue monitoring platform that enables continuous, real-time measurement of tissue oxygen directly within the body. The technology is designed for use both in clinical settings and at home, with the goal of supporting long-term monitoring of patients.

Profusa reports that the Lumee Oxygen platform has been evaluated in clinical studies, including a U.S.-based pilot study in peripheral artery disease (PAD) patients. Data presented at Paris Vascular Insights indicated that Lumee oxygen traces strongly correlated with transcutaneous partial pressure of oxygen (tcpO₂), that both Lumee and tcpO₂ detected oxygen decreases during occlusion, that sensors remained functional for up to one year, and that no sensor placement-related adverse events were reported in that study. Profusa states that these results support Lumee as a safe and effective long-term method for monitoring PAD patients and are expected to support a potential U.S. FDA submission.

In Europe, Profusa has described the Lumee Oxygen Platform as its first offering, designed to report reliable tissue oxygen levels at regions of interest over both acute and long-term time frames. The company has highlighted applications in peripheral artery disease, chronic wounds, critical limb threatening ischemia (CLTI) and other vascular conditions where tissue oxygenation is an important parameter for clinical decision-making.

Commercial stage digital health model

Profusa describes itself as a commercial stage digital health company. Its public statements emphasize the combination of tissue-integrated biosensors with an intelligent data platform that together are intended to deliver medical-grade, continuous biochemical data. The company has indicated that its Lumee technology is being positioned for use in hospitals, outpatient care, and wound care and healing clinics, particularly for patients with complex and chronic wounds and for those with PAD or CLTI.

Profusa has also outlined plans to work with distributors and clinical collaborators in Europe to support commercialization of Lumee Oxygen tissue monitoring. The company has referenced agreements or intended partnerships with specialized medical device distributors and vascular centers, and has indicated that these relationships are part of its strategy to build a commercial footprint across multiple European countries.

Clinical collaborations and vascular focus

Profusa’s news releases describe collaborations with vascular surgeons and vascular centers in Europe and the United States. For example, the company has announced that vascular specialists in France and Greece are adopting Lumee Oxygen tissue monitoring in clinical practice and in clinical studies. These collaborations are described as focusing on applications such as measuring tissue oxygen perfusion before and during revascularization procedures and throughout follow-up in hospitals or wound care clinics.

Profusa has also highlighted its participation in major vascular and interventional conferences, including Paris Vascular Insights and the Leipzig Interventional Course (LINC). At these meetings, the company has presented data from its U.S.-based pilot clinical study of Lumee in PAD patients and has emphasized the potential of its tissue oxygen monitoring technology as a biochemistry monitoring platform designed for both clinic and home use.

Capital markets status and corporate structure

Profusa’s common stock trades on The Nasdaq Stock Market LLC under the symbol PFSA. The company has described itself as an emerging growth company and a smaller reporting company in its SEC filings. In 2025, Profusa completed a business combination with NorthView Acquisition Corporation, and subsequent SEC filings refer to Profusa, Inc. as the registrant with its principal executive offices in Berkeley, California.

The company has engaged in multiple capital-raising and financing arrangements, including senior secured convertible promissory notes and an equity line of credit with Ascent Partners Fund LLC. Profusa’s filings describe a tranche-based note structure and an equity line facility that together provide potential access to capital, subject to conditions such as Nasdaq listing compliance and effective registration statements.

Profusa has also sought stockholder approvals for matters such as increasing its authorized common shares and authorizing potential reverse stock splits within a specified range. Proxy statements and related filings indicate that these corporate actions are intended to support financing flexibility and compliance with Nasdaq listing rules.

Nasdaq listing compliance considerations

In an October 2025 Form 8-K, Profusa reported receiving a Nasdaq notification that the company was not in compliance with the minimum Market Value of Publicly Held Shares requirement for the Nasdaq Global Market. The filing states that this notice had no immediate effect on the listing or trading of the company’s common stock and that Profusa was granted a period to regain compliance, with the possibility of appealing any delisting determination or applying to transfer to The Nasdaq Capital Market if needed.

Subsequent proxy materials describe a special meeting of stockholders to consider, among other items, a proposal authorizing the board of directors to effect one or more reverse stock splits within a specified ratio range, at its discretion, prior to a defined future date. The stated purpose of this proposal is to give the board flexibility to implement a reverse split if it determines such an action would be in the best interests of the company and its stockholders.

Regulatory and reporting profile

Profusa files periodic reports and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-Q, 8-K, proxy statements on Schedule 14A, and registration statements on Form S-1. In a Form 12b-25 (Notification of Late Filing), the company disclosed that it required additional time to finalize disclosures for a quarterly report and expected to file within the permitted extension period. The company has also filed proxy statements for special meetings related to financing transactions and changes to its certificate of incorporation.

Through these filings, Profusa provides information on its capital structure, financing arrangements, authorized share count, and proposals for stockholder approval. The company’s status as an emerging growth company allows it to take advantage of certain reduced reporting requirements under U.S. securities laws.

Intellectual property and branding

Profusa has disclosed that “LUMEE”, “PROFUSA” and the Profusa logo are registered trademarks of Profusa Inc. in the United States, Canada, the European Union, China, Japan, South Korea and Australia. These trademarks relate to the company’s biosensor platform and its branding in connection with tissue oxygen monitoring and related technologies.

Future indications and platform potential (as described by the company)

In its public communications, Profusa has outlined potential future indications for its tissue-integrated biosensor platform beyond oxygen monitoring. Company statements reference the potential for continuous glucose monitoring and other analytes such as lactate, carbon dioxide, sodium and ethanol, which Profusa has indicated may be evaluated through partnerships or licensing agreements. These descriptions are presented by the company as part of a broader platform vision for continuous biochemistry monitoring.

Profusa has also discussed its view of the addressable market for tissue oxygen monitoring across conditions such as peripheral artery disease, chronic wounds and critical limb ischemia, and has provided its own revenue projections and timelines for commercialization in Europe and the United States. These forward-looking statements are subject to the usual uncertainties associated with regulatory approvals, market adoption and financing, and are described in the company’s press releases and investor materials.

Summary

Overall, Profusa, Inc. is a healthcare and medical technology company focused on tissue-integrated biosensors and digital health data. Its Lumee Oxygen tissue monitoring platform is designed to measure tissue oxygen continuously and in real time, with applications in vascular and wound care. The company is listed on Nasdaq under the symbol PFSA, operates as an emerging growth company, and has pursued financing structures and corporate actions intended to support commercialization of its technology and maintain exchange listing. All information summarized here is based on Profusa’s own public statements, press releases and SEC filings.